Does tafamidis help treat patients with transthyretin amyloid cardiomyopathy?
A Multicenter, International, Phase 3, Double Placebo-Controlled, Randomized Study to Evaluate the Efficacy, Safety, and Tolerability of Daily Oral Dosing of Tafamidis Meglumine (PF-06291826) 20 mg or 80 mg in Comparison to Placebo in Subjects Diagnosed With Transthyretin Cardiomyopathy (TTR-CM)
Category & Conditions: Cardiovasular Diseases and Conditions
Medicine: VYNDAQEL® (TAFAMIDIS MEGLUMINE) CAPSULES AND VYNDAMAX™ (TAFAMIDIS) CAPSULES
ClinicalTrials.gov Identifier (NCT): NCT01994889
Protocol ID: B3461028
PrintDownloadOpen Plain Language Summary Result: Click here